Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans

Viola Klück¹, Rosanne C. van Deuren¹, Amara Shaukat², Maartje Cleophas¹, Tania O. Crisan³, Nicola Dalbeth⁴, Lisa K. Stamp⁵, Tim Jansen⁶, Matthijs Janssen⁶, Alexander Hoischen¹, Frank van de Veerdonk⁷, Mihai Netea¹, Charles Dinarello⁸, Elan Z. Eisenmesser⁹, Vassili Kalabokis¹⁰, Soohyun Kim¹¹, Tony R. Merriman¹² and Leo .A.B. Joosten¹, ¹Experimental Internal Medicine, Radboud Institute of Molecular Life Sciences, Nijmegen, Netherlands, ²University of Otago, Dunedin, New Zealand, ³Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, ⁴Bone Rsch Grp/Dept of Med, University of Auckland, Auckland, New Zealand, ⁵Department of Medicine, University of Otago, Christchurch, New Zealand, ⁶VieCuri Medical Center, Venlo, Netherlands, ⁷Department of General Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁸Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, ⁹Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, CO, ¹⁰R&D Systems, BioTechne, Inc., Minneapolis, MN, ¹¹Laboratory of Cytokine Immunology, Konkuk University, Seoul, Korea, Republic of (South), ¹²Department of Biochemistry, School of Medical Sciences, University of Otago, Dunedin, New Zealand

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: genetics, Gout and interleukins (IL)

Session Information

Date: Tuesday, October 23, 2018

Title: Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: During a gout flare monosodium urate (MSU) crystals induce, in the presence of a secondary stimulus, acute joint inflammation characterized by the recruitment of predominantly neutrophils. These neutrophils release chemokines and inflammatory mediators, further amplifying the inflammation. IL37 emerges as a fundamental inhibitor of the innate immune response and inhibits MSU-crystal induced inflammation in cell lines and murine models of gout. To further elucidate the role of IL37 in gout, we examined DNA of people with gout for genetic variations in IL37 and assessed the functional consequences of these mutations.

Methods: Exons of the IL37 gene were sequenced using Molecular Inversion Probes (MIPs) in 677 people with crystal-proven gout. The frequency of rare genetic variants in IL37 was compared to a cohort of 469 healthy controls and a cluster analysis was performed.
Neutrophils were isolated from healthy Dutch donors, pretreated with IL37, a genetic variant of IL37 or IL37Fc (the tail region of an antibody to IL37) and stimulated with opsonized MSU crystals. Reactive oxygen species (ROS) and IL8 production were measured.
For the validation of genetic variants, a total of 2202 clinically-ascertained gout cases and 2295 controls (further stratified into 424 hyperuricemic (≥0.41mmol/L) controls) of European and NZ Māori and Pacific (Polynesian) ancestry were utilized. Taqman® genotyping was carried out, followed by multivariate-adjusted association analysis with gout as the outcome.

Results: MIP-sequencing identified 4 non-synonymous rare variants in exon 5 of IL37 in 6 gout patients, whereas none were detected in the healthy controls (fisher’s exact test; p=0.043). Two variants (p.H172HX; p.N182S), present in two individuals, were observed in the Exome Aggregation Consortium database; the private variants (p.A144P; p.C181*) were not. Cluster analysis showed the rare variants in IL37 significantly cluster (p= 5.71 E10^-5).
To elucidate the effect of mutations in IL37, a recombinant protein was produced based on the p.C181* mutation. In vitro, full length IL37(46-218) significantly decreased ROS and IL8 production. The IL37 mutant demonstrated diminished anti-inflammatory effects compared to the full-length protein.
In our validation cohort, the rs752113534 variant (p.N182S) was monomorphic in people of European ancestry, but the minor G-allele exhibited a frequency of 0.05 in people of Eastern and Western Polynesian ancestry. A meta-analysis of people of Eastern and Western Polynesian ancestry showed a significant association of the G-allele with gout risk using hyperuricemic controls (OR= 1.81, P_OR=0.03). As a potential therapeutic, IL37Fc was tested in vitro and strongly inhibited ROS and IL8 production.

Conclusion: Rare genetic variants in IL37 clustering in exon 5 were found in people with gout. One of these IL37 mutants demonstrated a loss of the anti-inflammatory function in vitro. Moreover, the association of IL37 rare variant rs752113534 in prevalent gout in people of Polynesian ancestry supports a role for IL37 in an inflammatory pathway leading to gout in the presence of hyperuricemia. Furthermore, IL37Fc was identified as a potential new therapeutic in the treatment of gout.

Disclosure: V. Klück, None; R. C. van Deuren, None; A. Shaukat, None; M. Cleophas, None; T. O. Crisan, None; N. Dalbeth, None; L. K. Stamp, None; T. Jansen, None; M. Janssen, None; A. Hoischen, None; F. van de Veerdonk, None; M. Netea, None; C. Dinarello, None; E. Z. Eisenmesser, None; V. Kalabokis, RandDsystems, 3; S. Kim, None; T. R. Merriman, None; L. A. B. Joosten, None.

To cite this abstract in AMA style:

Klück V, van Deuren RC, Shaukat A, Cleophas M, Crisan TO, Dalbeth N, Stamp LK, Jansen T, Janssen M, Hoischen A, van de Veerdonk F, Netea M, Dinarello C, Eisenmesser EZ, Kalabokis V, Kim S, Merriman TR, Joosten LAB. Genetic Variants Identify Interleukin 37 As an Important Anti-Inflammatory Cytokine in Gout in Humans [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/genetic-variants-identify-interleukin-37-as-an-important-anti-inflammatory-cytokine-in-gout-in-humans/. Accessed .

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetic-variants-identify-interleukin-37-as-an-important-anti-inflammatory-cytokine-in-gout-in-humans/